TY - JOUR
T1 - Imaging of pulmonary hypertension in adults
T2 - A position paper from the Fleischner Society
AU - Remy-Jardin, Martine
AU - Ryerson, Christopher J.
AU - Schiebler, Mark L.
AU - Leung, Ann N.C.
AU - Wild, James M.
AU - Hoeper, Marius M.
AU - Alderson, Philip O.
AU - Goodman, Lawrence R.
AU - Mayo, John
AU - Haramati, Linda B.
AU - Ohno, Yoshiharu
AU - Thistlethwaite, Patricia
AU - Van Beek, Edwin J.R.
AU - Knight, Shandra Lee
AU - Lynch, David A.
AU - Rubin, Geoffrey D.
AU - Humbert, Marc
N1 - Funding Information:
Support statement: M. Humbert is supported by the Investissement d’Avenir program managed by the French National Research Agency under the grant contract ANR-18-RHUS-0006 (DESTINATION 2024).
Funding Information:
Conflict of interest: M. Remy-Jardin received payment for lectures including service on speakers’ bureaus from Siemens Healthineers, Boehringer Ingelheim, Roche, and MSD, outside the submitted work. C.J. Ryerson disclosed no relevant relationships. M.L. Schiebler disclosed no relevant relationships. A.N.C. Leung disclosed no relevant relationships. J.M. Wild disclosed no relevant relationships. M.M. Hoeper is board member and consultant for Acceleron, Actelion, Bayer, Janssen, MSD, and Pfizer, received payment for lectures including service on speakers bureaus from Acceleron, Actelion, Bayer, Janssen, MSD, and Pfizer, outside the submitted work. P.O. Alderson disclosed no relevant relationships. L.R. Goodman disclosed no relevant relationships. J. Mayo received payment for lectures including service on speakers’ bureaus from Siemens Healthineers Canada, outside the submitted work. L.B. Haramati disclosed no relevant relationships. Y. Ohno received research grant from Canon Medical Systems, during the conduct of the study; has grants/grants pending with Bayer Pharma, outside the submitted work; received grants-in-aid for scientific research from the Japanese Ministry of Education, Culture, Sports, Science and Technology; received research grant from Smoking Research Foundation; received research grant from Daiichi Sankyo. P. Thistlethwaite disclosed no relevant relationships. E.J.R. van Beek is board member of Aidence, Imbio, and QCTIS, is a consultant for InHealth and Mentholatum, outside the submitted work; is owner and founder of QCTIS; author and spouse are directors. S.L. Knight disclosed no relevant relationships. D.A. Lynch is a consultant for Parexel Imaging, Boehringer Ingelheim, Veracyte, Daiichi Sankyo, and AstraZeneca, received payment for lectures including service on speakers bureaus from Boehringer Ingelheim, outside the submitted work. G.D. Rubin disclosed no relevant relationships. M. Humbert is a board member and consultant for Acceleron, Actelion, Bayer, GSK, and Merck; has grants/grants pending with Acceleron, Actelion, and Bayer; received payment for lectures including service on speakers bureaus from Actelion, Bayer, GSK, and Merck, outside the submitted work.
Publisher Copyright:
© 2021 European Respiratory Society. All rights reserved.
PY - 2021/1/1
Y1 - 2021/1/1
N2 - Pulmonary hypertension (PH) is defined by a mean pulmonary artery pressure greater than 20 mmHg and classified into five different groups sharing similar pathophysiologic mechanisms, haemodynamic characteristics, and therapeutic management. Radiologists play a key role in the multidisciplinary assessment and management of PH. A working group was formed from within the Fleischner Society based on expertise in the imaging and/or management of patients with PH, as well as experience with methodologies of systematic reviews. The working group identified key questions focusing on the utility of CT, MRI, and nuclear medicine in the evaluation of PH: A) Is noninvasive imaging capable of identifying PH? b) What is the role of imaging in establishing the cause of PH? c) How does imaging determine the severity and complications of PH? d) How should imaging be used to assess chronic thromboembolic PH before treatment? e) Should imaging be performed after treatment of PH? This systematic review and position paper highlights the key role of imaging in the recognition, work-up, treatment planning, and follow-up of PH.
AB - Pulmonary hypertension (PH) is defined by a mean pulmonary artery pressure greater than 20 mmHg and classified into five different groups sharing similar pathophysiologic mechanisms, haemodynamic characteristics, and therapeutic management. Radiologists play a key role in the multidisciplinary assessment and management of PH. A working group was formed from within the Fleischner Society based on expertise in the imaging and/or management of patients with PH, as well as experience with methodologies of systematic reviews. The working group identified key questions focusing on the utility of CT, MRI, and nuclear medicine in the evaluation of PH: A) Is noninvasive imaging capable of identifying PH? b) What is the role of imaging in establishing the cause of PH? c) How does imaging determine the severity and complications of PH? d) How should imaging be used to assess chronic thromboembolic PH before treatment? e) Should imaging be performed after treatment of PH? This systematic review and position paper highlights the key role of imaging in the recognition, work-up, treatment planning, and follow-up of PH.
UR - http://www.scopus.com/inward/record.url?scp=85099262272&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099262272&partnerID=8YFLogxK
U2 - 10.1183/13993003.04455-2020
DO - 10.1183/13993003.04455-2020
M3 - Article
C2 - 33399507
AN - SCOPUS:85099262272
SN - 0903-1936
VL - 57
JO - European Respiratory Journal
JF - European Respiratory Journal
IS - 1
M1 - 2004455
ER -